Pharvaris (PHVS) Capital Expenditures (2020 - 2026)
Pharvaris' (PHVS) quarterly Capital Expenditures came in at -$60992.3 in Q1 2026, up 63.99% YoY from -$37193.7 in Q1 2025, and down 3306.82% on a QoQ basis from -$1790.3 in Q4 2025.
Pharvaris (PHVS) Capital Expenditures (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Capital Expenditures data on file, last reported at -$60992.3 in Q1 2026.
- Quarterly Capital Expenditures rose 63.99% year-over-year to -$60992.3 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$65829.1 (up 90.87% YoY) and the FY2025 annual result came in at -$185988.4, up 68.06% from the prior year.
- Capital Expenditures fell to -$60992.3 in Q1 2026, from -$1790.3 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $58.9 billion in Q3 2023 to a low of -$58.9 billion in Q2 2023.
- A 5-year average of -$1.1 million and a median of -$30535.2 in 2023 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 114742419.94% in 2023, down 236328759.87% in 2023.
- Tracing PHVS's Capital Expenditures over 5 years: stood at -$24117.6 in 2022, then declined by 26.61% to -$30535.2 in 2023, then sank by 463.14% to -$171955.2 in 2024, then soared by 98.96% to -$1790.3 in 2025, then tumbled by 3306.82% to -$60992.3 in 2026.
- The last three Capital Expenditures figures came in at -$60992.3 (Q1 2026), -$1790.3 (Q4 2025), and -$21877.7 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - | 152,386.80 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 152,386.80 |
| Jun 30, 2026 | 152,386.80 |
| Mar 31, 2026 | -60,992.34 |
| Mar 31, 2026 | -60,992.34 |
| Dec 31, 2025 | -1,790.30 |
| Dec 31, 2025 | -1,790.30 |
| Sep 30, 2025 | -21,877.70 |
| Sep 30, 2025 | -21,877.70 |
| Jun 30, 2025 | 18,831.28 |
| Jun 30, 2025 | 18,831.28 |
| Mar 31, 2025 | -169,356.55 |
| Mar 31, 2025 | -169,356.55 |
| Dec 31, 2024 | -171,955.17 |
| Dec 31, 2024 | -171,955.17 |
| Sep 30, 2024 | -336,412.09 |
| Sep 30, 2024 | -336,412.09 |
| Jun 30, 2024 | -43,221.96 |
| Jun 30, 2024 | -43,221.96 |
| Mar 31, 2024 | -33,360.00 |
| Mar 31, 2024 | -33,360.00 |